Watchlist Price Alert

Novavax Inc. (NVAX)

NASDAQ: NVAX · Real-Time Price · USD

6.37

-0.13 (-2.00%)

At close: Jun 27, 2025, 3:59 PM

6.41

0.71%

After-hours: Jun 27, 2025, 05:35 PM EDT

-2.00% (1D)

Bid	6.37
Market Cap	1.03B
Revenue (ttm)	1.25B
Net Income (ttm)	478.7M
EPS (ttm)	2.75
PE Ratio (ttm)	2.31
Forward PE	28.17
Analyst	Buy

Ask	6.57
Volume	2,699,597
Avg. Volume (20D)	9,002,635
Open	6.50
Previous Close	6.50
Day's Range	6.32 - 6.58
52-Week Range	5.01 - 17.81
Beta	2.77

About NVAX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol NVAX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for NVAX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Novavax Inc. is scheduled to release its earnings on Aug 7, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

-0.78%

Shares of vaccine stocks are trading higher follow... Unlock content with Pro Subscription

1 month ago

+15.01%

Moderna shares are trading higher after the company announced it received approval from the FDA for its COVID-19 vaccine and unlocked a milestone $175 million payment from Sanofi SA.

News

3 days ago · zacks.com

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

1 week ago · zacks.com

Novavax (NVAX) Ascends While Market Falls: Some Facts to Note

Novavax (NVAX) concluded the recent trading session at $6.41, signifying a +1.75% move from its prior day's close.

1 week ago · zacks.com

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

2 weeks ago · zacks.com

Novavax's COVID-Flu Combo Shot Shows Strong Immune Response

NVAX's COVID-flu combo shot sparks strong immunity in seniors, fueling plans for further late-stage trials.

2 weeks ago · seekingalpha.com

Novavax, Inc. (NVAX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Novavax, Inc. (NASDAQ:NVAX ) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 2:00 PM ET Company Participants James Patrick Kelly - Executive VP, CFO & Treasurer John Charles Jacob...

2 weeks ago · zacks.com

Novavax (NVAX) is a Top-Ranked Momentum Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

2 weeks ago · reuters.com

Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study

Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines showed strong immune responses in some patients tested in a late-stage study, the company said on Wednesday.

2 weeks ago · reuters.com

Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up

Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all members of an expert vaccin...